FierceBiotech  Jan 23  Comment 
European regulators are recommending approval for The Medicines Company's cangrelor, setting up an overseas nod for a blood-thinning drug rejected by the FDA last year.
Benzinga  Jan 7  Comment 
KaloBios Pharmaceuticals, Inc. (NASDAQ: KBIO) shares dipped 66.67% to $0.61 after the company reported top-line data from phase 2 study of KB001-A. LiqTech International, Inc. (NYSE: LIQT) shares fell 32.71% to $0.72. LiqTech International...
Market Intelligence Center  Dec 18  Comment 
MarketIntelligenceCenter.com's patented trade-picking algorithms have identified an attractive covered-call trade on Medicines Company (MDCO). Look at the Jul. '15 $26.00 covered call for a net debit in the $23.97 area. This trade has a duration...
Market Intelligence Center  Dec 5  Comment 
For a hedged play on Medicines Company (MDCO), MarketIntelligenceCenter.com’s option-trade picking algorithms recommend the Apr. '15 $25.00 covered call for a net debit in the $23.29 area. That is also the break-even stock price for the covered...
Market Intelligence Center  Nov 28  Comment 
Medicines Company (MDCO) presents a trading opportunity that offers a 11.40% return in just 231 days. A covered call on Medicines at the $26.00 level expiring on Jul. '15 offers an assigned return rate of 11.40% or 18.01% annualized. This trade...
Benzinga  Nov 20  Comment 
Credit Suisse upgraded The Medicines Company (NASDAQ: MDCO) Thursday from Neutral to Outperform and raised its price target from $27 to $33. Analysts led by Jason Kantor noted that “investor sentiment is currently very bearish and several...
Benzinga  Nov 5  Comment 
The Medicines Company (NASDAQ: MDCO) today announced enrollment of the first patient in its Phase 3 clinical trial program for CARBAVANCE™ (meropenem/RPX7009), an investigational intravenous antibiotic under development for the treatment of...
Market Intelligence Center  Nov 4  Comment 
After closing Monday at $25.58, Medicines Company (MDCO) presents an attractive opportunity to get a 4.91% return in just 74 days, which is an annualized return of 24.22% (for comparison purposes only). To enter this trade, sell one Jan. '15...
StreetInsider.com  Oct 27  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Medicines+Co.+%28MDCO%29+Wins+Angiomax+Patent+Dispute+vs+Mylan+%28MYL%29+-+Bloomberg/9944903.html for the full story.


Based in Parsippany, NJ, The Medicines Company (MDCO) is engaged in acquiring, developing, and marketing specialty pharmaceutical primarily for cardiovascular indications. Its leading product, Angiomax (bivalirudin), which was acquired from Biogen Idec, Inc. in 1996, is used as an anticoagulant in patients undergoing coronary angioplasty. The company's other late-stage products include Clevidipine and Cangrelor, both acquired from AstraZeneca several years ago. Clevidipine is an intravenous drug (calcium channel blocker) intended for the short-term control of blood pressure in patients undergoing cardiac surgery. Cangrelor is an intravenous anticoagulant, having potential uses in coronary angioplasty and cardiac surgery. The company sells its products through its own sales force and distributors. In 2006, sales of Angiomax helped generate $214.0 million revenue.


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki